$BOLD

TANG KEVIN purchased $156K of BOLD (indirect holdings)

TANG KEVIN purchased 63,969 indirectly-held shares of Boundless Bio, Inc. (BOLD) at an average of $2.43 ($2.43–$2.44, $0.16M total) across 3 trades over 2026-07-14 to 2026-07-16.

Original reporting
SEC EDGAR · TANG KEVIN
Published Jul 17, 2026, 12:10 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Jul 17, 2026, 12:34 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$BOLD
Bullish
medium confidence
Mentioned
$BOLD
Relevance
5/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$BOLDBullishLow
01

Why it matters

The newest concrete fact is the disclosed open-market purchase size, price range, and post-transaction share count for a 10% owner.

02

Market read

Traders may treat the filing as a small sentiment input, but it does not provide new operational or financial guidance.

03

What to watch

Indirect holdings and the absence of a stated rationale limit inference; traders should watch for subsequent filings (additional buys/sells) and any concurrent company-specific catalysts.

Relevance 5/10Novelty 5/10Timing: Filed after-hours on 2026-07-16, covering purchases from 2026-07-14 to 2026-07-16.

Background

This is an SEC Form 4 insider transaction disclosure for Boundless Bio, Inc. (BOLD).

Company-level read

Ticker impact

$BOLDBullishMedium confidence
Context

Boundless Bio insider Tang Kevin, a 10% owner, bought 63,969 shares in open-market trades at about $2.4331 between July 14-16.

Expected impact

Likely limited near-term impact; any effect should be small and sentiment-driven unless followed by additional disclosures.

Evidence & confidence

The filing is a primary Form 4 disclosure with transaction details, but it does not include new company performance, forecasts, or regulatory/contract events.

Market effects

No clear sector read-through from a single insider purchase without additional operational or regulatory context.

None indicated.

None indicated.

Counterpoint

The purchase is indirect and not under a pre-arranged 10b5-1 plan, but it still may reflect routine liquidity or portfolio rebalancing rather than a strong forward view.

Key entities

  • Boundless Bio, Inc.

    Subject of the Form 4 insider transaction disclosure.

  • TANG KEVIN

    10% owner who purchased shares indirectly via open-market trades.

Related articles